🇺🇸 FDA
Pipeline program

Rifaximin

VI27478

Unknown small_molecule active

Quick answer

Rifaximin for Bacterial Overgrowth Syndrome Small Bowel is a Unknown program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Bacterial Overgrowth Syndrome Small Bowel
Phase
Unknown
Modality
small_molecule
Status
active

Clinical trials